Logo

AC Immune Report Results of Semorinemab in P-II Lauriet Study for the Treatment of Alzheimer's Disease

Share this

AC Immune Report Results of Semorinemab in P-II Lauriet Study for the Treatment of Alzheimer's Disease

Shots:

  • The P-II Lauriet study evaluates the safety & efficacy of semorinemab (anti-tau mAb) vs PBO in 272 adult patients with AD across 43 centers globally. The therapy is being developed by Genentech
  • The trial met its one co-1EPs i.e 43.6% reduction in cognitive decline from baseline as measured by ADAS-Cog11 @49wks. The 2EPs were not achieved for ADCS-ADL & no effect on other co-primary EPs of reducing the rate of functional decline from baseline as measured by ADCS-ADL or 2EPs for MMSE & CDR-SB
  • Additionally- the safety profile was consistent with previous clinical data. Genentech to continue the open-label portion of the study & results will be submitted at CTAD in Nov’21

  | Ref: AC Immune | Image: AC Immune

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions